J Korean Diabetes.  2017 Mar;18(1):32-36. 10.4093/jkd.2017.18.1.32.

Diabetes and Tuberculosis

• Lee T

• KMID: 2374765
• DOI: http://doi.org/10.4093/jkd.2017.18.1.32

Abstract

Tuberculosis is still one of the major diseases in Korea. Recently, the number of tuberculosis patients with diabetes is increasing due to the increase in diabetes mellitus prevalence. Patients diagnosed with tuberculosis need a screening test for diabetes, and if diagnosed with diabetes, integrated management is needed. It is not yet strongly recommended to perform latent tuberculosis testing in people diagnosed with diabetes, for this, additional research is needed. In diabetic patients with tuberculosis, strict blood glucose control is needed, tuberculosis treatment could be prolonged, and insulin and metformin, which have no drug interaction with rifampin, are preferred.

Keyword

Diabetes mellitus; Tuberculosis

MeSH Terms

Blood Glucose
Diabetes Mellitus
Drug Interactions
Humans
Insulin
Korea
Latent Tuberculosis
Mass Screening
Metformin
Prevalence
Rifampin
Tuberculosis*
Blood Glucose
Insulin
Metformin
Rifampin

Reference

1. Joint Committee for the Revision of Korean Guidelines for Tuberculosis Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis, 2014. 2nd ed. Seoul: The Korean Academy of Tuberculosis and Respiratory Diseases;2014.

2. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010; 375:2100–2109.

3. World Health Organization. Global tuberculosis report. Geneva: World Health Organization;2015.

4. Centers for Disease Control and Prevention. Korean Guidelines for Tuberculosis. Cheongju: Centers for Disease Control and Prevention;2016.

5. Nunes-Alves C, Booty MG, Carpenter SM, Jayaraman P, Rothchild AC, Behar SM. In search of a new paradigm for protective immunity to TB. Nat Rev Microbiol. 2014; 12:289–299.

6. Long R, Ellis E, Elwood K. Public Health Agency of Canada. Canada Lung Association. Canadian tuberculosis standards. 6th ed. Ottawa: Public Health Agency of Canada;2007.

7. World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization;2015.

8. World Health Organization. Collaborative framework for care and control of tuberculosis and diabetes. Geneva: World Health Organization;2011.

9. Kapur A, Harries AD, Lönnroth K, Wilson P, Sulistyowati LS. Diabetes and tuberculosis co-epidemic: the Bali Declaration. Lancet Diabetes Endocrinol. 2016; 4:8–10.

10. Riza AL, Pearson F, Ugarte-Gil C, Alisjahbana B, van de Vijver S, Panduru NM, Hill PC, Ruslami R, Moore D, Aarnoutse R, Critchley JA, van Crevel R. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol. 2014; 2:740–753.

11. Pizzol D, Di Gennaro F, Chhaganlal KD, Fabrizio C, Monno L, Putoto G, Saracino A. Tuberculosis and diabetes: current state and future perspectives. Trop Med Int Health. 2016; 21:694–702.

12. Chang JT, Dou HY, Yen CL, Wu YH, Huang RM, Lin HJ, Su IJ, Shieh CC. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc. 2011; 110:372–381.